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The pharmacologic treatment of hypertension has been extensively studied by clinical trials.
These studies have provided definitive evidence of a treatment benefit, and the weight and
consistency of the clinical evidence has led to uniformity in many aspects of treatment
recommendations worldwide. However, controversies remain—in particular, whether specific
classes of drug therapy offer benefits for cardiovascular disease prevention beyond the expected
benefits of blood pressure lowering per se. Updated large-scale epidemiologic studies and the
meta-analysis of clinical trial data have better informed this debate and emphasized that the
main driver of clinical benefit from blood pressure-lowering therapy is the magnitude of blood
pressure reduction and perhaps the speed at which it is achieved. However, clinical trials are
of short duration, and there are more marked drug-specific differences in intermediate
cardiovascular structure, functional, and metabolic end points. The challenge is to interpret
their significance with regard to longer term outcomes. Finally, although blood pressure
lowering is undoubtedly beneficial, the concepts of single risk factor intervention and arbitrary
blood pressure thresholds and treatment goals are being challenged by the recognition that the
real target is cardiovascular disease risk. Undoubtedly, the most effective way to “go beyond
blood pressure” is to add a statin. (J Am Coll Cardiol 2005;45:813–27) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.069American College of Cardiology Foundation
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bhe benefits of lowering blood pressure are no longer
isputed and are supported by the most impressive evidence
ase in clinical medicine. The most recent World Health
rganization report highlighted the importance of blood
ressure as a major cardiovascular risk factor when it
dentified hypertension as the single most important pre-
entable cause of premature death in developed countries
1). Consequently, international guidelines have advocated
ver more aggressive screening and treatment strategies.
Despite the certainty of therapeutic benefit, numerous
ontroversies have emerged and many remain. Are there
rug-specific benefits that go beyond the powerful indepen-
ent benefits of blood pressure lowering? Conversely, are
ertain classes of drugs potentially “harmful” with regard to
pecific outcomes, and does this offset the potential benefit
f blood pressure lowering? Are clinical trials, which focus
n higher risk patients and “hard clinical end points,” the
est way to assess the potential benefits of drug treatments
hat are likely to be applied for half of a patient’s lifetime?
re we endeavoring to prevent events or prevent the
volution of a destructive disease process? In this regard,
hat is the role of surrogate or intermediate end points?
nd finally, just what is hypertension in 2005? Is it
ppropriate to have an arbitrary threshold to define “hyper-
ension,” or should we instead consider the benefits of
From the Department of Cardiovascular Sciences, University of Leicester School of
edicine, Leicester, United Kingdom. Dr. Williams has received honoraria for
ectures and consultancy and research grants from numerous pharmaceutical compa-
ies involved in the manufacture of blood pressure-lowering drugs.o
Manuscript received September 8, 2004; revised manuscript received October 16,
004, accepted October 18, 2004.blood pressure-lowering” in the context of a patient’s
verall cardiovascular disease (CVD) risk? These are key
uestions that have been addressed and in many instances
enerated by the results of recent clinical trials. The purpose
f this review is to critically evaluate these important
uestions and concepts.
VOLUTION OF CLINICAL TRIALS OF
LOOD PRESSURE-LOWERING DRUGS
o fully appreciate the complexity and challenges in inter-
reting hypertension trials, it is informative to review their
volution. The prospective, randomized, clinical trial has
een the foundation for evaluating the effectiveness of blood
ressure-lowering drugs. The duration of clinical trials
arely exceeds five years, and trials focus on so-called “hard
nd points”—notably, all-cause mortality and/or cause-
pecific morbidity and mortality due to CVD, usually
oronary heart disease (CHD) and/or stroke, but more
ecently heart failure (HF) as well. The early clinical trials
ad the advantage of being able to compare “active therapy”
ith placebo and usually included patients with more severe
ypertension, as compared with modern trials. Conse-
uently, they generated more end points and had sufficient
ower to be conducted on a smaller scale than modern trials.
s the benefits of blood pressure lowering became apparent,
t became unethical to include a placebo group. This led to
he modern “head-to-head” trials, which no longer focused
n whether blood pressure lowering, per se, was beneficial,
ut whether treatment based on different drug classes would
ffer advantages “beyond blood pressure lowering.” This
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Treatment of Hypertension and Cardiovascular Risk March 15, 2005:813–27pproach aimed to minimize the blood pressure difference
etween the treatment arms, thereby reducing the power of
he studies, which markedly increased the numbers of
atients and the study duration to maximize power. This
lso led to the emergence of “the composite primary end
oint” (i.e., a combination of events), because despite their
onsiderable size, trials rarely had the power to examine key
ause-specific outcomes.
Trial design has been further complicated by the tight-
ning of treatment thresholds, which has meant that most
atients require multiple drugs to achieve the blood pressure
oals. Thus, trials no longer compared individual drug
lasses, but rather, they compared treatment regimens. This
omplexity has been compounded by the fact that the
ajority of patients at high CVD risk also receive concom-
tant medications such as statins and aspirin, which further
educes the likelihood of major CVD events and further
iminishes the power of the trial, thereby mandating trials
f ever increasing size and cost. These considerations are
ugely important when reviewing the results of clinical trials
ith regard to the certainty to which benefits can be
ttributed to individual drugs.
ETA-ANALYSIS OF BLOOD
RESSURE-LOWERING DRUG TRIALS
s indicated earlier, the more recent trials of blood
ressure-lowering therapies have usually used a composite
rimary end point because of insufficient power to examine
mportant individual cause-specific outcomes. To address
mportant questions about drug safety and outcomes with
pecific drug classes, the data from recent trials have been
ooled and subjected to meta-analyses (2–4). This aggre-
ation of data provides much greater statistical power with
hich to examine drug-specific effects.
The Blood Pressure Lowering Treatment Trialists Col-
aborative (BPLTTC) published their most recent meta-
nalysis in 2003 (2). This incorporated data from 29
andomized, controlled trials involving 162,341 patients,
nd the mean duration of follow-up ranged from 2.0 to 8.0
ears, providing over 700,000 patient-years of follow-up.
he overall mean age of trial participants was 65 years, and
2% were men.
As expected, angiotensin-converting enzyme (ACE) in-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AF  atrial fibrillation
ARB  angiotensin receptor blocker
CCB  calcium channel blocker
CHD coronary heart disease
CI  confidence interval
CVD  cardiovascular disease
HF  heart failure
MI  myocardial infarctionibitors and calcium channel blockers (CCBs) were both iore effective than placebo at reducing the risk of major
ardiovascular events by 22% (confidence interval [CI] 17%
o 27%) and 18% (CI 5% to 29%), respectively (Fig. 1).
hen the main drug classes were compared “head-to-
ead,” (i.e., conventional therapy [thiazide and/or beta-
locker], ACE inhibitors, or CCBs), there were no signif-
cant differences in major cardiovascular outcomes or
ardiovascular mortality (Fig. 2). Similar conclusions were
eached in a second independent meta-analysis conducted
n behalf of the National Institute of Clinical Excellence
NICE) in the United Kingdom (Fig. 3) (4), and a quan-
itative overview of recent clinical trials (3), which included
he more recently published Controlled Onset Verapamil
nvestigation of Cardiovascular End Points (CONVINCE)
tudy (5).
REVENTION OF CHD
hen meta-analysis was used to examine the impact of
CE inhibitors or CCBs on CHD events, both reduced
HD risk to a similar order of magnitude versus placebo, by
0% and 22%, respectively (Fig. 1) (2,3). Moreover, when
ompared head-to-head, there was no evidence that any one
lass of drug was more effective than any other at preventing
HD events (Figs. 2 and 3) (2–4). This is important
ecause it fails to confirm popular perception that ACE
nhibition provides special protection against CHD events,
r that conventional or CCB-based therapy is less effective
han ACE inhibition at CHD prevention in people with
reated hypertension.
Few data were available for the angiotensin receptor
lockers (ARBs) when these analyses were conducted, but
here is no evidence from existing data from three ARB-
ased trials (Study on COgnition and Prognosis in the
lderly [SCOPE], Losartan Intervention For Endpoint
eduction in hypertension [LIFE], and Valsartan Antihy-
ertensive Long-term Use Evaluation [VALUE]) that
RBs are any more or less effective at preventing CHD
han can be expected from their action to lower blood
ressure (6–9).
Thus, for CHD prevention, the benefits accrued from
lood pressure-lowering appear to be directly attributable to
he blood pressure reduction rather than the drug classes
sed to achieve it. This conclusion is endorsed by reference
o specific trials such as the Antihypertensive and Lipid
owering treatment to prevent Heart Attack Trial (ALL-
AT), the largest ever blood pressure-lowering therapy
rial, with sufficient power to specifically examine CHD
orbidity and mortality as its primary end point (10). In the
LLHAT study, the primary outcome occurred in 2,956
articipants, and there were no differences between the rates
ith the reference drug, a thiazide-like diuretic; chlorthali-
one (11.5%), a CCB; amlodipine (11.3%), an ACE inhib-
tor; or lisinopril (11.4%) (9).
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ith regard to stroke prevention, the BPLTTCmeta-analysis
evealed some interesting trends. Not surprisingly, ACE in-
ibitor or CCB-based therapy reduced the risk of stroke by
8% and 38%, respectively, as compared with placebo (Fig. 1)
2). Of interest, compared with conventional therapy, ACE
nhibitor-based therapy was marginally less effective at prevent-
ng fatal/nonfatal stroke in both the BPLTCC and NICE
eta-analyses (Figs. 2 and 3) (2,4). This may surprise many,
indful of the publicity surrounding ACE inhibitor-based
tudies such as the Heart Outcomes Prevention Evaluation
HOPE) study (11,12) and Perindopril Protection Against
ecurrent Stroke Study (PROGRESS) (13), which reported
reater stroke prevention with ACE inhibitor-based studies
nd implied “drug-specific benefits beyond blood pressure
owering.” It is important to note that these two studies
ompared ACE inhibitor-based treatment with placebo—a
omparison that inevitably resulted in greater blood pressure
owering with ACE inhibition. As discussed subsequently,
hese differences in blood pressure are more than sufficient to
ccount for the cardiovascular benefits observed in these two
rials. Moreover, when ACE inhibition has been compared
head-to-head” with other blood pressure-lowering drugs (the
igure 1. Effect of angiotensin-converting enzyme inhibitors (ACEi) and calc
BP) lowering on cause-specific cardiovascular outcomes. The overall mean BP
alues in the “first listed.” CI  confidence interval. Reproduced from the Blaptopril Prevention Project [CAPPP] [14], the Swedishrial in Old Patients with Hypertension-2 [STOP-2] [15],
LLHAT [10], the Second Australian National Blood Pres-
ure Study [ANBP-2] [16]), there is no suggestion from any of
hese trials of superior stroke prevention by ACE inhibition.
In contrast to ACE inhibition, the BPLTTC and NICE
eta-analyses showed that CCB-based therapy tended to
e more effective than conventional therapy and ACE
nhibition at stroke prevention (Figs. 2 and 3) (2,4). Similar
rends have been reported by others (3,17,18).
A more marked benefit for stroke prevention was seen by
eta-analysis of ARB-based therapy, as compared with
ther treatments (2). This relates to data from two trials:
COPE and LIFE (6–8). The SCOPE trial is less infor-
ative with regard to “drug-specific benefits” because it
andomized hypertensive patients to ARB-based treatment
candesartan) versus placebo, which inevitably resulted in a
ignificant blood pressure difference between the treatment
roups (6). However, a recent analysis of the cohort of
atients with isolated systolic hypertension from the
COPE trial revealed a patient population in whom the
lood pressure difference was only 2/1 mm Hg in favor of
andesartan and in whom there was a 42% reduction in
troke with the ARB-based treatment (7).
hannel blockers (CCBs) versus placebo and “more versus less” blood pressure
ence between treatments is shown. Negative values mean lower blood pressure
ressure Lowering Treatment Trialists’ Collaboration (2), with permission.ium c
differ
ood PThe LIFE study compared ARB-based treatment (losar-
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Treatment of Hypertension and Cardiovascular Risk March 15, 2005:813–27an) with atenolol-based treatment in over 9,000 people
ith hypertension and left ventricular hypertrophy by elec-
rocardiography. There was a significant 25% reduction in
he rate of fatal or nonfatal stroke in those randomized to
osartan-based therapy (8). Of interest, this benefit was not
bserved in hypertensive black patients within the LIFE
tudy, the reasons for which remain unclear (19). In the
ore recent VALUE trial comparing ARB-based treatment
valsartan) with CCB-based treatment (amlodipine), there
as no evidence of greater stroke prevention with the
RB-based therapy (9). On the contrary, there was a trend
oward 15% fewer strokes (p  0.08) in those randomized
o the CCB-based regimen. In the VALUE trial, blood
ressure was significantly lower throughout the trial with
CB-based therapy, perhaps explaining the trend toward
etter stroke prevention with CCB. In the LIFE trial, much
maller intergroup blood pressure differences were apparent,
nd mean arterial blood pressures appeared similar for both
reatment arms throughout the study. Some have calculated
bserved and predicted odds ratios for stroke in clinical trials
nd concluded that even the small blood pressure differences
n the LIFE trial are sufficient to account for the observed
ifference in stroke rates (Table 1) (3). Others have sug-
igure 2. Comparison of blood pressure (BP)-lowering regimens based o
econd treatment regimens are shown. Negative blood pressure values in
onverting enzyme inhibitor; CCB  calcium channel blocker; CI 
eproduced from the Blood Pressure Lowering Treatment Trialists’ Collaested that the benefit of losartan-based treatment in LIFE way be due to the deficiency of beta-blocker–based treat-
ent in preventing stroke, rather than a specific advantage
f the ARB (20–22). This provocative hypothesis is not
upported by the BPLTTC meta-analysis of stroke preven-
ion with conventional therapy, which includes beta-
lockade (2), or the NICE meta-analysis (4), both of which
uggest that beta-blocker–based treatments prevent stroke
n proportion to the blood pressure reduction they produce.
Another major trial will soon better inform this debate
bout the effectiveness of beta-blocker/thiazide diuretic-
ased therapy. The blood pressure-lowering arm of the
nglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
23) has compared conventional blood pressure lowering
ased on treatment with a beta-blocker (atenolol) with or
ithout a thiazide (bendroflumethiazide-K) with a more
ontemporary regimen based on a CCB (amlodipine) with
r without an ACE inhibitor (perindopril) in almost 20,000
atients with hypertension. This study was recently stopped
arly based on the advice of the Data Safety Monitoring
oard because of significant and important benefits with
egard to major cardiovascular outcomes associated with the
ontemporary treatment regimen based on the CCB with or
ithout ACE inhibitor. It has not yet been reported
erent drug classes. Mean blood pressure differences between the first and
e lower pressures with the first treatment listed. ACEi  angiotensin-
ence interval; D/B  diuretic- and/or beta-blocker–based regimens.
ion (2), with permission.n diff
dicathether this relates to better blood pressure control with the
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March 15, 2005:813–27 Treatment of Hypertension and Cardiovascular Riskontemporary regimen. Whatever the mechanism, this find-
ng from the ASCOT study, which will be reported fully
ater in 2005, suggests that modern treatments are more
ffective than the traditional beta-blocker/thiazide diuretic
egimen at reducing major cardiovascular outcomes in
eople with hypertension.
EART FAILURE PREVENTION
he end point of HF is not an easy diagnosis to validate
utside the hospital and has been a contentious issue in
ypertension trials. An example is the ALLHAT trial,
here HF rates were much higher than those reported in
ther studies randomizing people of comparable baseline
VD risk (10). One possible explanation for this higher
han usual rate of HF in the ALLHAT trial rests with the
rial design—patients were crossed over from their usual
ntihypertensive therapy to the trial drug at randomization,
ithout a washout period. The majority (90%) were treated
ypertensive patients before randomization, and mindful of
igure 3. Effect of blood pressure lowering in different studies compar
ngiotensin-converting enzyme (ACE) inhibitor–based regimens (botto
egimens on cardiovascular outcomes and all-cause mortality. CI confiden
xcellence Clinical Guideline 18 (4), with permission.he mean age of the study population (67 years), it is likelyhat many patients were receiving diuretic therapy before
andomization. Subsequent randomization to drugs other
han a diuretic means it is perhaps not surprising that HF
as diagnosed significantly more often over six years in
hose randomized to either amlodipine or lisinopril, perhaps
ue to the unmasking of existing HF by diuretic with-
rawal.
Using a definition of HF that caused death or admission
o the hospital, meta-analyses suggest that there is a clear
enefit of ACE inhibitor-based treatments over placebo
Fig. 1) (2,3). No such benefit has been demonstrated for
CB-based therapy as compared with placebo or compared
ith treatments based on ACE inhibition or conventional
herapy (Figs. 1 and 2). Of interest, by meta-analyses, for
he treatment of hypertension, there was no evidence that
CE inhibition was more effective at preventing HF than
onventional therapy. However, this conclusion is strongly
nfluenced by the data from the ALLHAT study, with all of
he aforementioned caveats.
alcium (Ca) channel blocker-based treatment regimens (top panel) or
nel) versus thiazide (Th/Thi/Thiaz.) and/or beta-blocker (BB)–based
terval; RR risk ratio. Reproduced from the National Institute of Clinicaling c
m paThe ARBs appear to prevent HF more effectively than
t
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Treatment of Hypertension and Cardiovascular Risk March 15, 2005:813–27he comparator drugs used in the LIFE and SCOPE trials
6,8). However, the VALUE study did not confirm a
ignificant advantage of treatment based on the ARB
alsartan compared with CCB-based treatment (amlodip-
ne) for the prevention of HF (hazard ratio 0.89, 95% CI
.77 to 1.03, p  0.12) (9). In the VALUE trial, there was
late trend in favor of the ARB, but overall, the study is
ifficult to interpret because of greater diuretic use in the
alsartan arm of the study and significant differences in
lood pressure control in favor of amlodipine.
MPACT OF GENDER
he impact of gender on the effectiveness of blood pressure
owering at reducing cardiovascular events was addressed by
he INDANA Working Group using a meta-analysis of
ndividual patient data from seven randomized clinical trials
omprising 40,777 patients, of whom 49% were men (24).
n this analysis overall, the risk ratios did not differ between
en and women for any of the major outcomes, and there
as no significant interaction between treatment effect and
ender. This conclusion is supported by reference to the
LLHAT study, the largest study published since the
NDANA analysis. The ALLHAT study showed no evi-
Table 1. Observed Odds Ratios for Myocardia
Trials Versus the Odds Ratios Predicted by In
From Previous Trials Comparing Older Versus
Study
SB
(mm H
ALLHAT—thiazide (chlorthalidone)
versus amlodipine
Myocardial infarction
1.
Stroke
ALLHAT—thiazide versus lisinopril
Myocardial infarction
2.
Stroke
ALLHAT—thiazide versus lisinopril in
black Americans
Myocardial infarction
4.
Stroke
ANBP-2—thiazide (hct) versus enalapril
Myocardial infarction
1.
Stroke
CONVINCE—atenolol or thiazide
versus verapamil
Myocardial infarction
0.
Stroke
LIFE—atenolol versus losartan
Myocardial infarction
1.
Stroke
SCOPE—placebo  thiazide (hct) (80%)
versus candesartan
Myocardial infarction
3.
Stroke
SBP refers to the difference in treated systolic blood pressure
pressure control on “older” drugs, usually thiazides and/or b
confidence intervals (CI) calculated from the data in the spec
by meta-regression analysis. The p value refers to the significa
first- and second-listed initial therapies. Adapted from dataence of any significant difference in major cardiovascularutcomes, including coronary events between men and
omen, irrespective of drug allocation at randomization
10).
MPACT OF ETHNICITY
he effects of ethnicity on cardiovascular outcomes in blood
ressure-lowering trials has been poorly studied. Until
ecently, most trials had predominantly included white
aucasians with poor representation from black, Asian, and
ispanic patients. This is an important consideration be-
ause of ethnic influences on the blood pressure-lowering
fficacy of different drug classes. For example, people of
lack African descent more commonly have a “low renin”
henotype and in general exhibit a poorer blood pressure-
owering response to monotherapy with drugs that inhibit
he renin system, such as ACE inhibition, ARBs, or
eta-blockers, as compared with CCBs or thiazide diuretics
25,26). This almost certainly explains the outcome in the
0,702 black Americans (35% of study population) in the
LLHAT study in whom ACE inhibition was much less
ffective at preventing stroke compared with chlorthalidone,
ost likely due to poorer blood pressure control with ACE
nhibition in the black American cohort (10).
rction and Stroke From Specific Clinical
up Differences in Systolic Blood Pressure
er Blood Pressure-Lowering Regimens
Observed OR
(CI)
Predicted OR
(CI) p Value
0.99 (0.90–1.08) 1.06 (0.93–1.20) 0.37
0.94 (0.82–1.07) 1.00 (0.89–1.12) 0.43
0.98 (0.90–1.08) 1.14 (0.98–1.34) 0.08
1.15 (1.05–1.30) 1.08 (0.94–1.24) 0.51
1.10 (0.94–1.28) 1.29 (1.05–1.59) 0.20
1.4 (1.17–1.68) 1.23 (1.03–1.47) 0.31
0.70 (0.49–1.00) 1.08 (0.95–1.23) 0.02
1.05 (0.79–1.38) 1.02 (0.90–1.15) 0.83
0.81 (0.64–1.03) 0.99 (0.89–1.09) 0.14
1.15 (0.89–1.48) 0.92 (0.83–1.02) 0.11
1.07 (0.87–1.31) 0.93 (0.85–1.02) 0.24
0.75 (0.63–0.90) 0.87 (0.79–0.95) 0.15
1.11 (0.77–1.59) 0.84 (0.77–0.92) 0.96
0.76 (0.57–1.02) 0.77 (0.71–0.84) 0.92
een treatment groups. A negative value indicates better blood
ockers. The observed odds ratios (OR) are shown  95%
al. The 95% CI for the predicted ORs have been calculated
the difference between predicted and observed OR between
essen et al. (3).l Infa
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March 15, 2005:813–27 Treatment of Hypertension and Cardiovascular Riskesponse to blood pressure-lowering drugs in other ethnic
roups—notably, Hispanic or Asian. The ALLHAT study
andomized 5,246 Hispanic Americans (19% of study pop-
lation), and there did not appear to be any heterogeneity in
heir cardiovascular benefits from different treatments (10).
uch less data are available for Asian patients with hyper-
ension, but modern trials are increasingly recruiting pa-
ients from the Asia-Pacific region, which will address this
eficiency. From the limited data available, there does not
ppear to be any reason to anticipate major differences in
rug-specific outcomes.
RUG SAFETY: LESSONS LEARNED
he randomized clinical trial is as much a test of drug safety
s it is of efficacy. This became important in the late 1990s
hen controversy first emerged about the safety of CCBs
especially short-acting CCBs) for the treatment of hyper-
ension (27–29). This controversy was initially founded on a
etrospective case-controlled study suggesting that CCBs,
specially short-acting ones, may be associated with an
nhanced risk of CHD, as compared with alternative
reatments (27). Such analyses are fatally flawed by the
normous potential for confounding by drug indication.
urther data from the premature stopping of a small clinical
rial suggesting less effective prevention of CHD with
CBs in people with type II diabetes (30) fueled the
ontroversy.
Subsequently, data from a series of large, prospective,
andomized, clinical trials comparing CCBs head-to-head
ith other blood pressure-lowering therapies, such as the
ntervention as a Goal In Hypertension Treatment
INSIGHT) study, the Nordic Diliazem (NORDIL) study,
LLHAT, CONVINCE, the International Verapamil-
randolapril Study (INVEST), and VALUE, have dis-
issed these concerns (5,9,10,31–33). The ALLHAT study
as specifically powered to test the CHD hypothesis as its
rimary end point and definitively showed effective CHD
revention with a CCB (amlodipine), including in those
ith diabetes (10). More recently, the VALUE trial further
ested this hypothesis and included CHD events in its
rimary end point. In the VALUE trial, amlodipine was
ctually superior to valsartan-based therapy at protecting
gainst fatal and nonfatal myocardial infarction (MI), as
ell as reducing the frequency of angina (9). These two very
arge trials confirm the conclusions from the aforemen-
ioned meta-analyses (Figs. 2 and 3), notably that, for CHD
revention, no one class of blood pressure-lowering drug
as been shown to be any less or any more effective than any
ther; their benefits are primarily determined by how
ffectively they lower blood pressure. The important mes-
age from this turbulent time is that case-control studies can
e seriously misleading and must always be interpreted with
reat caution. There is no substitute at present for random-
zed, controlled trials for formulating health policy and
reatment guidelines. cMPORTANCE OF BLOOD
RESSURE CONTROL REVISITED
n improved understanding of the importance of blood
ressure lowering has been a key advance from recent
linical studies. This issue has been central to the contro-
ersy and debate about whether drugs provide “benefits
eyond blood pressure control,” which is discussed in more
etail subsequently.
From an epidemiologic perspective, new data have clar-
fied the importance of blood pressure as a risk factor for
VD. In the largest and most detailed analysis, information
rom one million adults with no known vascular disease at
aseline, included in 61 prospective observational studies of
he relationship between blood pressure and mortality, was
xamined (34). This meta-analysis related outcomes per
ecade of age to the estimated usual blood pressure at the
tart of that decade. At ages 40 to 69 years, each difference
n usual systolic blood pressure of 20 mm Hg was associated
ith a more than two-fold difference in stroke death rate, as
ell as a two-fold difference in the death rate from CHD or
ther vascular causes (Fig. 4). These proportional differ-
nces in cardiovascular mortality were about half as extreme
n those who were 80 to 89 years old as compared with those
0 to 49 years old (i.e., the relative risk is steeper in younger
ge groups), but the absolute differences in risk are of course
reater in older age. Thus, throughout age, usual blood
ressure is strongly and directly related to cardiovascular
ortality across all blood pressure values, with no evidence
f a threshold down to 115/75 mm Hg, below which there
re insufficient data. Consistent with this conclusion, data
rom Framingham have shown a doubling in the cumulative
ncidence of cardiovascular events in those with a “high-
ormal” blood pressure (120 to 139/80 to 89 mm Hg), as
ompared with those with a “normal” blood pressure
120/80 mm Hg) (35), observations that led to the
mergence of the term “pre-hypertension” for those with
igh-normal blood pressures in Joint National Committee
JNC) VII (36).
With regard to intervention studies, meta-analyses have
xamined the impact of “more versus less” blood pressure
owering in clinical trials to determine whether there is
vidence for substantial cardiovascular benefits with seem-
ngly small blood pressure changes (Fig. 1) (2). Blood
ressure difference of 4/3 mm Hg in 20,888 patients
roduced a 23% reduction in the relative risk of stroke, as
ell as a 15% reduction in CHD events, a 16% reduction in
F, and a 14% reduction in total mortality. The weighted
lood pressure differences between treatment groups seemed
o be directly related to the differences in the risk of stroke,
HD, major CVD events, CVD death, and total mortality
2,3). In contrast, the magnitude of blood pressure differ-
nce in clinical trials did not appear to predict the risk of HF
2). These data suggest that in general and apart from HF,
lood pressure differences between treatment groups in
linical trials predict differences in outcome for all major
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Treatment of Hypertension and Cardiovascular Risk March 15, 2005:813–27ardiovascular events, even when blood pressure differences
re seemingly small. Moreover, there is no blood pressure
hreshold below which benefits cease, down to 115/75 mm
g. These latter two observations are critical to the debate
f the “beyond blood pressure” hypothesis championed by
igure 4. Age-specific hazard ratios for specified differences in usual systoli
IHD), and other vascular events. Data from 61 prospective observational
isease at baseline. CI  confidence interval. Reproduced from the Prosphe HOPE trial and the European trial On reduction of 1ardiac events with Perindopril in stable coronary Artery
isease (EUROPA) (11,37).
The VALUE trial strongly supports the blood pressure
ypothesis. The VALUE trial compared ARB-based ther-
py (valsartan) with CCB-based therapy (amlodipine) in
and diastolic (B) blood pressures. Impact on stroke, ischemic heart disease
es of blood pressure and mortality in one million adults with no vascular
Studies Collaboration (34), with permission.c (A)
studi
ective5,245 patients with hypertension at high risk of cardiac
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isease, stroke, or diabetes. It is informative to review the
ard end points traditionally associated with hypertension
rials—notably, fatal and nonfatal MI or stroke. There were
9% fewer MIs (p  0.02) and a trend toward 15% fewer
trokes (p  0.08) in those randomized to the CCB-based
egimen as compared with the ARB-based treatment. There
ere no significant differences in HF hospitalization or
ll-cause death (9).
The fact that blood pressure control was not equivalent in
oth arms of the VALUE trial provides an important
nsight into the power of seemingly small differences in
lood pressure to drive major differences in end points in
arge clinical trials of people at high CVD risk. Closer
xamination of the data for the first few months of the
ALUE trial reveals striking, indeed alarming differences in
nd point rates (at least two-fold differences) between the
wo treatment arms when there was the greatest disparity in
lood pressure control (i.e., 3/2 mm Hg) (Fig. 5) (9,38).
f note, these blood pressure differences are remarkably
imilar to those reported in many trials in which ACE
nhibition was compared with placebo, and such blood
ressure differences were dismissed as irrelevant to drug-
riven differences in outcome (11,37).
BEYOND BLOOD PRESSURE”
ccepting that: 1) the increased CVD risk attributable to
lood pressure is linear and extends across a wide range of
ressures down to 115/75 mm Hg; and 2) even small
eductions in blood pressure have a dramatic effect in
igh-risk patients, what is the evidence to support the view
hat some classes of blood pressure-lowering therapy can
rovide benefits “beyond blood pressure” (i.e., benefits that
annot be accounted for by blood pressure reduction)? This
ypothesis has been founded primarily on data from clinical
rials with ACE inhibitors and on the flawed premise that
hen treating people with “normal blood pressures” (i.e.
140/90 mm Hg), blood pressure lowering is unlikely to be
n important determinant of outcome.
In the light of all of the new data cited in this article, it
s instructive to reflect on the interpretation of the HOPE
tudy—the study that has provided the greatest impetus for
he “beyond blood pressure” hypothesis (11). The HOPE
tudy randomized a total of 9,297 patients 55 years old to
reatment with either ramipril (10 mg/day) or matching
lacebo for five years. The patients were deemed to be at
igh CVD risk due to a history of CHD, stroke, peripheral
ascular disease, or diabetes, plus at least one other cardio-
ascular risk factor. Almost 50% had treated hypertension.
he mean baseline blood pressure was 139/79 mm Hg,
uggesting a significant proportion of patients had a baseline
lood pressure above that value. The primary outcome of
he study was a composite of MI, stroke, or death from
ardiovascular causes and was reduced by 22% (p  0.001)
n favor of ramipril. Compared with placebo, treatment with Eamipril also reduced the rates of death from cardiovascular
auses by 26% (p  0.001), reduced MI by 20% (p 
.001), stroke by 32% (p  0.001), and death from any
ause by 16% (p  0.005). These risk reductions are
emarkably similar to those reported in the BPLTTC
eta-analysis, which compared ACE inhibitor therapy with
lacebo, for these specific end points (Fig. 1) (2).
There has been much controversy about the difference in
lood pressure between the ramipril- and placebo-treated
atients in the HOPE trial (39). The in-study clinic blood
ressure difference was reported to be 3/2 mm Hg in favor
f ramipril; however, a subsequent small study in HOPE
atients reported mean 24-h ambulatory blood pressure
ifferences of 11/4 mm Hg in favor of ramipril, even though
he clinic pressure difference was similar to that reported for
he main HOPE study population (40). Such substantial
ifferences in 24-h pressure would more than account for
he differences in cardiovascular outcomes reported for the
OPE study.
EUROPA, a more recent study, mimicked the HOPE
tudy design by randomizing patients at high cardiovascular
isk (i.e., documented coronary disease, 65% with previous
I) to the ACE inhibitor perindopril (8 mg/day) or
lacebo for five years of follow-up (37). The patients were
normotensive” at baseline (mean blood pressure 137/82
m Hg) although 27% were treated hypertensives. Blood
ressure was 5/2 mm Hg lower with perindopril than with
lacebo, and this was associated with a 14% reduction in
otal mortality and 24% reduction in MI. Once again, these
isk reductions are similar to those reported from the
PLTTC meta-analysis when ACE inhibitors were com-
ared with placebo, with an identical blood pressure differ-
nce (Fig. 1) (2).
A more conservative and perhaps more scientifically
ccurate interpretation of the data from the HOPE and
igure 5. Odds ratios for the primary end point (composite of cardiac end
oints), major cause-specific outcomes, and total mortality during the first
hree months of the VALUE trial after patients had been randomized to
ither valsartan or amlodipine monotherapy. Change in blood pressure
BP) at three months refers to the lower mean blood pressures in patients
andomized to amlodipine. Data are expressed as the odds ratios  95%
onfidence intervals (CI). Figure is adapted from data extracted from Julius
t al. (9).UROPA studies is that blood pressure lowering, even in
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Treatment of Hypertension and Cardiovascular Risk March 15, 2005:813–27hose patients with seemingly “normal” blood pressures
according to the arbitrary definition of hypertension) is
eneficial, especially in patients at high baseline CVD risk,
nd moreover, that the benefit gained is entirely consistent
ith that expected from the magnitude of blood pressure
owering. This conclusion is further supported by an analysis
omparing the observed odds ratios for risk reduction from
linical trials such as the HOPE and EUROPA studies
rom those predicted on the basis of blood pressure lowering
n other trials. This analysis concluded that the observed
dds ratios fell well within the 95% confidence interval of
he odds ratio predicted by blood pressure fall alone (3).
More recently, the Prevention of Events with Angioten-
in Converting Enzyme Inhibition (PEACE) study retested
he HOPE trial hypothesis and compared the ACE inhib-
tor trandolapril with placebo in 8,290 patients at high risk
f CVD with a mean baseline blood pressure of 133/78 mm
g (41). There was no difference in the primary end point
death from cardiovascular causes, MI, or coronary revascu-
arization) after a median follow-up of almost five years.
his clear lack of benefit of ACE inhibition was observed
espite a lower blood pressure (3/1 mmHg vs. placebo) in
he ACE inhibitor-treated patients. This finding remained
hen the primary end point was adjusted to reflect the
dentical end point used in HOPE. This finding further
efutes the popular notion that ACE inhibition provides
enefit “beyond blood pressure” in patients without left
entricular dysfunction—in the words of one eminent com-
entator, may this concept “rest in PEACE” (42).
Finally, if ACE inhibition offered such “added value”
eyond blood pressure with regard to CVD prevention,
hen this would have been observed in trials in which ACE
nhibitors have been compared head-to-head with other
ctive blood pressure-lowering drugs. This has not been the
ase. In trials such as the ALLHAT, CAPPP, and STOP-2
10,13,14) studies, there was no evidence that ACE inhi-
ition is superior to conventional blood pressure lowering
or the prevention of CHD or stroke. The main “outlier” to
his conclusion is ANBP-2, which showed a borderline
ignificant benefit of ACE inhibitor-based therapy versus
hiazide diuretic-based therapy for some end points but not
thers. Interestingly, where there was benefit, it was only
een in males (16)! The data from ANBP-2 have been
ncluded in the aforementioned meta-analyses and do not
lter the conclusions from objective assessment of the
otality of the evidence (2–4). Moreover, the recent Com-
arison of Amlodipine Versus Enalapril to Limit Occur-
ences of Thrombosis (CAMELOT) study compared the
ffectiveness of an ACE inhibitor (enalapril), a CCB (am-
odipine), or placebo on cardiovascular events in 1,991
atients with angiographically proven CHD and a normal
verage baseline blood pressure (129/78 mm Hg), over a
wo-year follow-up period (43). The primary composite end
oint of cardiovascular events was significantly reduced by
mlodipine versus placebo (hazard ratio 0.69, 95% CI 0.54
o 0.088, p  0.003), primarily because of a reduction in hospitalization due to angina. Of interest, there was no
ignificant difference between enalapril and placebo for the
rimary end point. The CAMELOT study provides two
mportant insights: first, along with the VALUE trial (9), it
urther dismisses the ill-founded concerns about the safety
f CCBs (at least amlodipine) in patients with CHD. On
he contrary, both of these recent studies demonstrate a
lear treatment benefit. Second, in a direct head-to-head
rial with an active comparator, the CAMELOT study has
ailed to demonstrate any specific treatment benefit of ACE
nhibition in patients with established CHD. Moreover, a
ubstudy in the CAMELOT study used intravascular ultra-
ound (IVUS) to assess the impact of treatment on changes
n coronary atheroma volume (43). The IVUS study
termed NORMALISE) showed progression of atheroma
ver two years in the placebo group and a trend toward
rogression of atheroma in the group treated with enalapril.
n contrast, there was a trend toward less progression of
theroma in the group treated with the CCB amlodipine,
hich was significant in those with a systolic blood pressure
bove the mean at baseline.
This assessment of all of the recent head-to-head trials
oes not support the view that ACE inhibition prevents
ajor cardiovascular events beyond the benefits attributable
o blood pressure lowering in clinical trials.
EPORTING BLOOD PRESSURE PARAMETERS
N CLINICAL TRIALS: THE NEED FOR CLARITY
nother important caveat to the “beyond blood pressure”
ebate is that the information provided with regard to
in-trial” blood pressures is often very limited and invariably
nadequate. The data emphasized in study reports usually
efer to mean blood pressure parameters at the end of the
tudy (i.e., in those patients who complete the study). This
rovides no information with regard to potentially greater
in-trial” differences before the end of the study, perhaps
est exemplified by the much larger blood pressure differ-
nces early in the VALUE study (9). Concentrating on
lood pressure data at the end of the study clearly has the
otential to minimize the true “in-trial” blood pressure
ifferences between treatment comparisons. Moreover, by
efinition, the data at the end of the study represents the
ohort of study participants who have survived the study and
hus does not include the patients who suffered major end
oints earlier in the study. Thus, we have little or no data on
he blood pressures of the patients we are most interested in
i.e., those who suffered a major clinical event). As a
inimum requirement it would be helpful to know patients’
lood pressure parameters immediately before their clinical
vents or at least at the clinic visit preceding the event. This
ould surely be more informative to better understand the
elationship between achieved blood pressures and clinical
utcomes. The powerful relationship between achieved
lood pressures and clinical outcomes in high-risk patients
ighlights the need for trialists to develop more sophisti-
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March 15, 2005:813–27 Treatment of Hypertension and Cardiovascular Riskated analyses of individual patient blood pressure data,
ntegrated throughout the trial. Without such data, it is
mpossible to dismiss the impact of blood pressure differ-
nces on outcome.
REVENTING DISEASE VERSUS PREVENTING EVENTS
lthough clinical trials have been important in confirming
he potent efficacy of blood pressure lowering, there is a
ownside to our dependence on clinical trials to validate
ong-term treatment. To prevent CVD, many people will be
reated for decades, whereas the clinical trial is of relatively
hort duration. Moreover, to ensure adequate end points,
linical trials recruit older patients at high CVD risk, often
ith established and severe CVD. In effect, trials are
esigned to assess the prevention of “events” rather than the
evolution of the disease process” that will ultimately cul-
inate in events. In this regard, it is perhaps not surprising
hat it has been difficult to show drug-specific benefits with
egard to preventing acute CHD events in patients with
uch advanced disease.
Much of the experimental data postulating a direct role
or the renin-angiotensin-aldosterone system (RAAS) in
he development of CVD have advocated mechanisms that
re more relevant to the evolution of structural changes,
ascular inflammation, and the development of atheroma
44–48). Indeed, most studies in animal models using
AAS blockade are studies of “disease prevention” (i.e.,
reventing the development of atheroma or reversal of
tructural changes, rather than preventing cardiovascular
vents) (44,46–48). Conceptually, it is easier to envision
ow subtle but important and favorable effects on vascular
tructure and function, over a prolonged time, may ulti-
ately have an impact on survival, rather than influence the
erminal stages of the disease process over a shorter duration
f time. Clearly, lowering blood pressure appears to be able
o influence the entire spectrum of the disease process (i.e.,
isease evolution and short-term events), whereas drug-
pecific benefits and, in particular, blockade of the RAAS
ay provide a more subtle but prolonged benefit. This is
peculative but highlights the difficulties in endeavoring to
ranslate clinical trial data from older, high-risk patients in
he truncated time frame of a clinical trial, to a broader more
eterogeneous population at various stages of disease evo-
ution. Consequently, it would be premature to dismiss the
otential nonhemodynamic benefits of specific drugs alto-
ether.
This concept is particularly relevant to younger patients
ho have the potential to be exposed to drug therapy for
any decades and for whom there is limited outcomes data.
ost clinical trials, to ensure adequate event rates, limit
ecruitment to patients above the age of 55 years and have
sually reported a mean age of the study populations of
ore than 65 years. Thus, younger patients are poorly
epresented in outcome trials. This is a concern as modern
VD prevention strategies increasingly advocate the impor- pance of primary prevention and treatment of an increasing
umber of younger patients. It is conceivable that in
ounger patients, subtle differences in drug effects on various
urrogate or “intermediate” disease markers could have an
mportant beneficial impact over the longer term.
URROGATE OR INTERMEDIATE
ISEASE MARKERS: DO THEY MATTER?
ecent clinical studies have examined the impact of differ-
nt blood pressure-lowering drugs on resistance vessel
tructure (44), intima-medial thickness in larger arteries
49), left ventricular mass and structure (8,45), new-onset
trial fibrillation (AF) (50–52), systemic inflammatory
arkers (53), albuminuria (54–57), and metabolic changes
ulminating in new-onset diabetes (see subsequent text).
hese studies have consistently shown that blockade of the
AAS has favorable effects on these surrogate parameters
eyond that attributable to blood pressure lowering alone.
n many instances, this potential benefit has not necessarily
ranslated into a reduction in cardiovascular events in
linical outcome trials, perhaps because their impact on the
isease process takes more time to evolve than the typically
horter duration of a clinical trial. A good example of this
omes from the ALLHAT study, in which treatment with
hlorthalidone was associated with significantly more new-
nset diabetes than treatment with amlodipine or lisinopril
10). The CHD event rates were little different, despite the
act that diabetes is usually associated with at least a
oubling in CHD risk. One explanation for this apparent
nomaly is that there was insufficient time within the trial
or the new-onset diabetes to exert its impact on CHD
utcomes.
Another example relates to new-onset AF. Atrial fibril-
ation occurs more commonly in people with hypertension
nd greatly increases the risk of all cardiovascular events,
specially stroke (58). In the ALLHAT study, patients with
F at baseline experienced a three-fold increased risk of
ortality, a doubling in risk of fatal or nonfatal CHD, and
four-fold increase in the risk of stroke, as compared with
hose without AF at baseline (10). In the LIFE trial,
ew-onset AF was reduced by 28% (p  0.001) with
osartan-based therapy, as compared with atenolol-based
herapy, suggesting a role of angiotensin II in the induction
f AF (51), a conclusion supported by some (50) but not
ther recent studies (9).
It seems reasonable to conclude that if such surrogate
enefits were maintained over the longer term, that they
ight ultimately translate into a reduced morbidity and
ortality. As longer term trials are unlikely to be performed,
e are left with the challenge of trying to weigh the relative
mportance of these surrogate benefits alongside the proven
enefits of blood pressure lowering. Perhaps that weighting
hould be greater when considering treatment of younger
atients in whom the opportunities for preventing structural
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Treatment of Hypertension and Cardiovascular Risk March 15, 2005:813–27amage will be greater and in whom avoiding the induction
f new-onset diabetes is particularly important.
EW-ONSET DIABETES: IMPACT OF
LOOD PRESSURE-LOWERING DRUGS
iabetes is reaching epidemic proportions in westernized
ocieties, and hypertension and diabetes are a lethal duo
59). Moreover, hypertension, per se, is associated with a
oubling of risk of developing type II diabetes (60). Previ-
us studies have suggested that newer drugs (often in
ombination with a thiazide) are associated with a signifi-
antly reduced likelihood of developing type II diabetes in
eople treated for hypertension as compared with people
reated with conventional therapy, especially when a beta-
locker and thiazide/thiazide-like diuretic are used in com-
ination (6–11,14,16,31–33). These are summarized in
able 2. This is not cosmetic, and previous studies have
mphasized that the development of diabetes in people with
reated hypertension is associated with an enhanced CVD
isk, beyond the period of observation traditionally associ-
ted with a clinical outcomes trial (61,62). A more recent
ong-term cohort study has quantified the risk associated
ith new-onset diabetes in people with treated hypertension
63). In 795 initially untreated hypertensive patients, 6.5%
ad type II diabetes at baseline, and new diabetes developed
n 5.8% during follow-up. Cardiovascular event rates in
hose without diabetes, developing new diabetes, or diabetes
t baseline were 0.97, 3.90, and 4.70  100 person-years,
espectively (p  0.0001). Blood glucose at baseline and the
se of a thiazide diuretic were independent predictors of
ew diabetes developing during follow-up. After adjustment
or various confounders, including blood pressure control,
he relative risks of a cardiovascular event with new diabetes
r previous diabetes were 2.92 and 3.57, respectively, as
ompared with those who did not develop diabetes (63).
hus, the development of diabetes during the treatment of
ypertension appears to substantially enhance cardiovascular
isk if patient follow-up is sufficiently long to recognize it.
urther work in this important area is necessary.
There are clearly differences in the likelihood of develop-
able 2. Percentage of Patients Developing Diabetes in Random
Study (Ref.) Risk Profile Treatment C
OPE (11) High CVD risk ACEi vs. CT
APPP (14) Hypertension ACEi vs. CT
LLHAT (10) High-risk hypertension ACE vs. CT
NBP-2 (16) Elderly hypertensive ACE vs. CT
NSIGHT (31) High-risk hypertension CCB vs. CT
ORDIL (32) High-risk hypertension CCB vs. CT
NVEST (31) Hypertension  CHD CCB vs. non–
LLHAT (10) High-risk hypertension CCB vs. CT
COPE (6) Elderly hypertension ARB vs. CT
IFE (8) Hypertension  LVH ARB vs. CT
ALUE (9) High-risk hypertension ARB vs. CCBCEi  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; C
herapy, usually thiazide and/or beta-blocker-based; CVD  cerebrovascular disease; LVHng new diabetes with the major classes of blood pressure-
owering drugs, and a hierarchy of risk for new diabetes can
e developed from the results of recent clinical trials. Drugs
hat block the renin-system (i.e., ACE inhibition and
RBs) have been shown to reduce the risk of new diabetes,
s compared with conventional therapy (7–10,14–16). The
CBs have also been shown to reduce new diabetes com-
ared with conventional diuretic-based therapy (9,10,31–
3). In the ALLHAT study, the rates of new diabetes were
hlorthalidone 	 amlodipine 	 lisinopril (10). In the
ALUE trial, ARB-based therapy (valsartan) was associ-
ted with less new diabetes than CCB-based therapy
amlodipine) (9). All of this suggests that conventional
herapy (i.e., thiazide and/or beta-blocker), especially when
ombined, is associated with the highest rate of new
iabetes. Blockade of the renin system with ACE inhibition
r ARBs appears to be associated with the lowest rate of
ew diabetes, with CCBs sitting between the two extremes.
his conclusion has been supported by a recent similar
nalysis (64). Two key questions that need to be addressed
rospectively are: 1) whether certain drugs (i.e., ACE
nhibitors or ARBs) can reduce the anticipated high rate of
ew diabetes in people with hypertension; and 2) whether it
atters. Current data cannot provide a definitive answer to
hese questions, but a suggested hierarchy is emerging
hich suggests that conventional therapy (beta-blocker
nd/or thiazide diuretics) probably enhances the baseline
isk of developing diabetes, CCB-based therapy is probably
eutral, and ACE inhibition or ARB-based therapy may
iminish the risk of developing diabetes.
The potential for conventional therapy to unfavorably
nfluence the development of diabetes in people with treated
ypertension has recently been incorporated into national
reatment guidelines in the United Kingdom (4,65). These
uidelines recommend avoiding the combination of thiazide
nd beta-blockers in people at higher risk of developing new
iabetes (i.e., people with a strong family history of diabetes,
besity, impaired fasting glucose levels, or those within
thnic groups that have high rates of diabetes). This is an
mportant example of how the differential effects of drugs on
Clinical Trials of Blood Pressure-Lowering Therapy
arison
New Diabetes
Rates (%)
Risk
Reduction p Value
3.6 vs. 5.4 32% 0.001
6.5 vs. 7.3 13% 0.05
8.1 vs. 11.6 33% 0.001
4.5 vs. 6.6 31% 0.0005
5.4 vs. 7.0 23% 0.05
4.3 vs. 4.9 8% 0.14
-based 7.0 vs. 8.2 15% 0.05
9.8 vs. 11.6 16% 0.04
4.9 vs. 6.0 20% 0.09
6.0 vs. 8.0 25% 0.001
13.1 vs. 16.4 23% 0.0001ized
omp
CCBCB  calcium channel blocker; CHD  coronary heart disease; CT  conventional
 left ventricular hypertrophy.
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endations in a sensible and pragmatic way; as the evidence
upporting this approach strengthens, it is likely to be
dopted elsewhere.
MPLICATIONS FOR MODERN TREATMENT:
ARGETING CVD RISK RATHER THAN HYPERTENSION?
he key debate over the next few years will not be whether
ne class of blood pressure-lowering drug is better than
nother, but rather what is the most effective therapeutic
trategy to reduce the overall CVD risk burden of individual
atients. The aforementioned evidence that blood pressure
s a potent risk factor for CVD across the full range of blood
ressure, extending from 115/75 mm Hg, questions the
ogic of thresholds for “normotension,” “pre-hypertension,”
nd “hypertension” (36). In people at high CVD risk,
owering their blood pressure will produce a benefit irre-
pective of whether they are hypertensive by any of the
urrent definitions. What is the logic of treating such a
atient with drugs if their systolic blood pressure is 143 mm
g, but not if their systolic pressure is 138 mm Hg? There
s no biologic plausibility for such thresholds. The sole
ustification for thresholds is to decide when to use blood
ressure-lowering drugs in people at low CVD risk and with
o preexisting CVD in whom the strategy would be
esigned to prevent the evolution of hypertensive injury.
It is also impossible to target treatment appropriately
ithout assessing the total CVD risk burden of the patient,
deally formally by risk charts or calculators (e.g., based on
ramingham). After all, the purpose of treatment is to
educe the risk of stroke and CHD, not just blood pressure!
his concept is important because many patients with
levated blood pressure exhibit features of the metabolic
yndrome and dyslipidemia that magnify their risk of stroke
nd CHD, beyond that crudely attributed to blood pressure
lone (66).
OING BEYOND BLOOD PRESSURE? ADD A STATIN
ust as it is not necessary to be “hypertensive” to benefit from
lood pressure lowering, it is also not necessary to have a
igh blood cholesterol level to benefit from statin therapy.
he data from the Heart Protection Study (67) and the
SCOT study (68) are very important complementary data
ith regard to CVD prevention. Both have both shown that
rrespective of baseline cholesterol or blood pressure, statin
herapy reduces the risk of stroke and CHD. Thus, from a
ragmatic and evidence-based perspective, the new target
hould be CVD risk, not its individual components. Con-
equently, most people with treated hypertension, especially
ales over the age of 50 years, are at sufficient CVD risk to
enefit from the addition of statin therapy which, they may
urther substantially reduce their risk of CHD by an
dditional 30% and stroke by an additional 25%. In my
iew, statins should and will become routine therapy in
eople with treated hypertension, especially those at highestVD risk, because they potently complement the primary
bjective of antihypertensive therapy—notably, to reduce
he risk of CHD and stroke. This is undoubtedly the most
ffective way to “go beyond blood pressure.”
This concept of targeting CVD risk has been endorsed by
uropean guidelines (69) and further advocated by the
polypill” concept (70). The latter was an important stim-
lus for debate in this area, but in my view, is limited by the
omplexity of the proposed pill and the lack of outcome data
upporting the use of some of its constituents.
The guideline issue is important because guidelines frame
he messages adopted by the clinicians in primary care,
here most of the preventive medicine strategies are under-
aken. Recent statements have appropriately advocated ever
ore aggressive cholesterol lowering (71,72). Nevertheless,
n my view, the “silo approach” to risk factor management
dopted by specialist societies and exemplified by JNC VII
36) will ultimately become an obstacle to effective CVD
isk factor management. The evidence demands a single
nified, evidence-based approach to identifying those with
ufficient CVD risk to benefit from effective and proven
ultifactorial interventions. Patients are only interested in
aving their risk reduced, and for most, this will require
ore than one drug, each targeting different aspects of risk.
n this regard, due credit must be given to the HOPE trial
nd its investigators for highlighting that, irrespective of
rbitrary thresholds, drugs that lower risk factors ultimately
ower risk—not exactly rocket science but still too bold for
ome.
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